葛兰素史克跌5%:FDA专家委员会拒绝批准BCMA ADC

生物制药小编
Jul 20, 2025

2025年7月17日,FDA肿瘤药物咨询委员会(ODAC)以5:3投票结果拒绝批准葛兰素史克BCMA DC新药,用于二线联合治疗复发性或难治性多发性骨髓瘤。Blenrep的PDUFA日期为7月23日。葛兰素史克当天股价跌5%,目前市值为745亿美元。DREAMM-7和DREAMM-8两项三期临床设计方案如下,主要终点为PFS。两项三期临床均达到PFS主要终点。DREAMM-7达到OS关键次要终点。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10